Evidence map›Paper›PMID 41543155›Full record

ArticleInternational journal of oncology2026

<p>Circ72309 modulates gemcitabine metabolism and gemcitabine sensitivity in pancreatic cancer: Serum Circ72309 levels as a potential predictor of treatment response</p>.

Naoko Sekiguchi, Hidenori Takahashi, Shogo Kobayashi, Kazuki Sasaki, Shinichiro Hasegawa, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Hirofumi Akita, Tadafumi Asaoka and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Naoko SekiguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Hidenori TakahashiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Shogo KobayashiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Kazuki SasakiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Shinichiro HasegawaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Yoshifumi IwagamiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Daisaku YamadaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Yoshito TomimaruDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Hirofumi AkitaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Tadafumi AsaokaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Takehiro NodaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Junzo ShimizuDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Koji TanakaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Ryota ChijimatsuCenter for Comprehensive Genomic Medicine, Okayama University Hospital, Kita‑Ku, Okayama 700‑8558, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Osaka 565‑0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Circular RNAs (circRNAs) are associated with various biological features of cancer, including chemosensitivity and the structural characteristics of circRNAs indicate their potential as liquid biomarkers. Gemcitabine is a cornerstone treatment for pancreatic cancer (PC). A deeper understanding of gemcitabine sensitivity and the exploration of clinically valuable liquid biomarkers that are predictive of gemcitabine sensitivity may contribute to the development of improved‑tailored treatment strategies for PC. The aim of the present study was to identify a candidate circRNA associated with gemcitabine sensitivity, investigate its biological functions and evaluate its potential as a liquid biomarker in predicting gemcitabine sensitivity. circRNA sequencing analysis was conducted to identify candidate circRNAs and the function of a candidate circRNA in modulating gemcitabine sensitivity was investigated

Indexed as

Antimetabolites, AntineoplasticBiomarkers, TumorDeoxycytidineDrug Resistance, NeoplasmPancreatic NeoplasmsRNA, CircularAgedApoptosisCell Line, TumorEquilibrative Nucleoside Transporter 1FemaleGemcitabineGene Expression Regulation, NeoplasticHumansMaleMiddle AgedAntimetabolites, AntineoplasticBiomarkers, TumorDeoxycytidineEquilibrative Nucleoside Transporter 1GemcitabineRNA, CircularSLC29A1 protein, humanbiomarkerscirculargemcitabinepancreatic neoplasmsRNA

Identifiers

PMID41543155
PMCPMC12823056

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.